The economics of managing patients with prostate cancer

Archivio Italiano di Urologia e Andrologia

Volumn 75, Issue 2, 2003, Pages 75-87

  Scattoni, Vincenzo ^a   Lazzaro, Carlo ^b   Rigatti, Patrizio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Economista Sanitario   (Italy)

Author keywords

Cost; Cost effective; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; IODINE 125; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ARTICLE; BRACHYTHERAPY; BUDGET; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG CHOICE; DRUG COST; DRUG EFFICACY; EARLY DIAGNOSIS; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MEDICAL INSTRUMENTATION; MEDICAL SPECIALIST; MEDLINE; METASTASIS; NEEDLE; OPERATION DURATION; PATIENT CARE; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SURVIVAL RATE; COST; ECONOMICS; MALE; PROSTATE TUMOR;

BRACHYTHERAPY; COSTS AND COST ANALYSIS; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 0038125952     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Crocetti E, Zappa M. Epidemiologia del tumore della prostata. In Martorana G (Ed), Il carcinoma prostatico (Urologia Oncologica su CD Rom), 1999
2. Ciatto S. Lo screening nel carcinoma della prostata. In Martorana G (Ed), Il carcinoma prostatico (Urologia Oncologica su CD Rom), 1999
3. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW Methods for the economic evaluation of health care programmes, 2nd ed. New York: Oxford University Press, 1997
4. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1987
5. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
6. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418
7. Barry MJ, Fleming C, Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? IV: Estimating the risks and benefits of an early detection programme. Urology 1995; 46:445
8. The Economist. Pocket World in Figures. London: Profile Books Ltd., 2000
9. Krahn MD, Mooney C, Eckman MH, et al. Screening for prostate cancer: a decision analysis view. J Am Med Assoc 1994; 272:773
10. Holtgrewe HL, Lukas B, Nielsen HB, et al. The economics of prostate cancer In: Murphy G, Khoury S, Partin A, Denis L (Eds), Proceedings of the 2nd International Consultation on Prostate Cancer Paris: Scientific Communications International, 1999; 499
11. Neymark N, Torfs K. Economics of urinary tract cancers: state of the art. Eur Urol 1997: 31 (Suppl 1):72
12. AAVV Costi economici delle varie opzioni terapeutiche. In: Linee guida per il carcinoma prostatico. Genova: AUrO, 1998; 87
13. Carlsson P, Hjertbjerg H, Jonsson B, Vahrenhorst E. The cost of prostatic cancer in a defined population. Stand J Urol Nephrol 1989; 23:93
14. Holmberg H, Carlson P, Kalman D, Varenhorst E. Impact on health costs of medical technologies used in management of prostate cancer. Scand J Urol Nephrol 1998; 32:195
15. Grover SA, Zowall H, Coupal L, Krahn MD. Prostate cancer: 12. The economic burden. CMAJ 1999; 160:685
16. Barre M, Nerstrom B, Overgoard J. The dilemma of prostate cancer. Acta Oncologica 1997; 36:681
17. Regione Lombardia. Servizio Sistema Informativo e Controllo Qualità/Servizio Risorse del Servizio Sanitario Regionale. D.G.R. N° VII/941 del 03/08/00. Aggiornamento delle tariffe delle prestazioni ospedaliere in regime di ricovero. http://www.dgsan.lombardia.it/Atti/Delibere.htm.
18. Brandeis J, Pashos C, Henning J, Litwin M. A nationalwide cost comparison of the principal treatments for early stage prostate cancer. J Urol 2000; 163, 7A
19. Zanetta GP, Ruffino E. Sistemi sanitari a confronto. Torino: B.L.U. Editoriale, 1996
20. Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1999; 45:1219
21. Ciezki JP, Klein EA, Angermeier KW, Ulchaker J, Zippe CD, Wilkinson DA. Cost comparison of radical prostatectomy and transperineal brachytherapy for localized prostate cancer. Urology 2000; 55:68
22. Ministero della Salute, Decreto ministeriale n. 2 del 20 dicembre 2002. Elenco dei medicinali rimborsabili dal Servizio Sanitario nazionale ai sensi dei decreto del Ministero della Salute 27 settembre 2002 recante la riclassificazione dei medicinali ai sensi dell'art. 9, commi 2 e 3, del decreto - legge 8 luglio 2002, n. 138 convertito dalla legge 8 agosto 2002, n. 178, pubblicato nel supplemento ordinario n. 200 alla Gazzetta Ufficiale - serie generale - n. 249 del 23 ottobre 2002, e succesive modificazioni. Roma: Supplemento ordinario alla Gazzetta Ufficiale n. 4 del 7 Gennaio 2003, Serie generale.
23. Bonzani RA, Striker HJ, Peabody JO, Menon M. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 1998; 160:2446
24. Rutquist L, Wilking N. Analogues of LHRH versus orchiectomy: Comparison of economic costs for castration in advanced prostatic cancer. Br J Cancer 1992; 65:927
25. Nicol D. Advanced prostate cancer: The role of high priced hormone treatment. Med J Aust 1993; 159:16
26. Vahrenhorst E, Carlsson P, Pedersen K. Clinical and economic considerations in the treatment of prostate cancer. Pharmacoeconomics 1994; 6:127
27. Kowalshi JW, Jamieson CA, Hoenberger JC, Cox E, Lubeck DP Peter CR. Medical costs of metastatic prostate cancer. J Urol 2000; 163, 8A